Toxicity of checkpoint inhibitors

被引：12

作者：

Schmerling, Rafael Aron ^{[1
]}

机构：

[1] Ctr Oncol Antonio Ermirio Moraes, Sao Paulo, Brazil

来源：

CHINESE CLINICAL ONCOLOGY | 2014年 / 3卷 / 03期

关键词：

Melanoma; immunotherapy; checkpoint; inhibitors; toxicity; immune-related adverse events;

D O I：

10.3978/j.issn.2304-3865.2014.08.03

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunologic checkpoint inhibitor is a new class of antineoplastic drugs which mechanism of action depends on the interaction with the immune system. The first in class was ipilimumab, anti-CTLA4, and soon the anti-PD1 (Programmed Death 1) and anti-PDL1 are expected to be available. Although the profile of adverse events is unique, they are predictable and, by complying with the guidelines available, the management of these drugs is safe in the great majority of patients. Here, it is provided a review of adverse events and their management.

引用

页数：8

共 40 条

[1] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].

Atkins, MB ;

Lotze, MT ;

Dutcher, JP ;

Fisher, RI ;

Weiss, G ;

Margolin, K ;

Abrams, J ;

Sznol, M ;

Parkinson, D ;

Hawkins, M ;

Paradise, C ;

Kunkel, L ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116

[2]

Baurain JF, 2012, J CLIN ONCOL S, V30

[3] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[4]

BULKLEY GB, 1975, CANCER, V36, P485, DOI 10.1002/1097-0142(197508)36:2<485::AID-CNCR2820360227>3.0.CO

[5]

2-M

[6] CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy [J].

Chambers, CA ;

Kuhns, MS ;

Egen, JG ;

Allison, JP .

ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :565-594

[7] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[8] Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review [J].

Dillon, P. ;

Thomas, N. ;

Sharpless, N. ;

Collichio, F. .

MEDICAL ONCOLOGY, 2010, 27 (04) :1127-1132

[9] Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma [J].

Frankenthaler, Amy ;

Sullivan, Ryan J. ;

Wang, Wei ;

Renzi, Sharon ;

Seery, Virginia ;

Lee, Mee-Young ;

Atkins, Michael B. .

MELANOMA RESEARCH, 2010, 20 (06) :496-500

[10] Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek [J].

Freeman, Gordon J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (30) :10275-10276

← 1 2 3 4 →